Vertex Pharmaceuticals Incorporated $VRTX Holdings Decreased by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC cut its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,560 shares of the pharmaceutical company’s stock after selling 76 shares during the period. Exencial Wealth Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $694,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. D.A. Davidson & CO. raised its stake in Vertex Pharmaceuticals by 1.1% during the second quarter. D.A. Davidson & CO. now owns 4,856 shares of the pharmaceutical company’s stock worth $2,162,000 after acquiring an additional 51 shares during the period. Klingman & Associates LLC bought a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $207,000. Phoenix Financial Ltd. acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $1,085,000. DekaBank Deutsche Girozentrale lifted its holdings in shares of Vertex Pharmaceuticals by 3.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 506,457 shares of the pharmaceutical company’s stock worth $223,484,000 after purchasing an additional 15,328 shares during the last quarter. Finally, Bogart Wealth LLC boosted its position in Vertex Pharmaceuticals by 32.6% during the 2nd quarter. Bogart Wealth LLC now owns 25,407 shares of the pharmaceutical company’s stock valued at $11,311,000 after purchasing an additional 6,240 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The stock was bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on VRTX shares. Guggenheim dropped their target price on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Royal Bank Of Canada dropped their price objective on shares of Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 5th. Morgan Stanley decreased their target price on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Finally, Scotiabank cut their price target on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $494.38.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $422.63 on Friday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a market capitalization of $108.36 billion, a PE ratio of 30.21 and a beta of 0.43. The company’s 50 day simple moving average is $398.38 and its 200 day simple moving average is $435.23.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the prior year, the firm posted ($12.83) earnings per share. The company’s revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.